Amyloid Beta Aggregation Inhibitor Undersupply for Low-Dose Detoxification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for protein misfolding diseases, particularly those associated with amyloid beta aggregation, are limited in efficacy, tolerability, and cost, and require high doses of inhibitors to achieve desired effects.

Innovation Solution

Administering a low dose of compound (1), which has a stoichiometric ratio of 1:10 with amyloid beta molecules, to inhibit amyloid beta aggregation, thereby achieving stronger detoxifying effects compared to traditional inhibitors that require stoichiometric excess.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If traditional inhibitors are used to inhibit amyloid beta aggregation, then aggregation inhibition is achieved, but high doses are required resulting in limited efficacy and higher cost

Engineering Contradiction:

Improvedose of inhibitorVSAvoidefficacy of treatment

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent changes the stoichiometric parameter from traditional excess (10:1 to 1000:1 inhibitor to amyloid beta) to a reversed ratio (1:10 to 1:1000), achieving superior efficacy at lower doses through this fundamental parameter inversion

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent inverts the conventional stoichiometric approach by using a deficit ratio where one inhibitor molecule addresses multiple amyloid beta molecules, reversing the traditional wisdom that more inhibitor is always better

Inventive Principle:

Principle #13The other way round (Inversion)

2Reliability

If high doses of inhibitors are administered to achieve desired aggregation inhibition, then aggregation is inhibited, but tolerability and cost-effectiveness deteriorate

Engineering Contradiction:

Improveaggregation inhibitionVSAvoidtolerability and cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent fundamentally changes the dose parameter from high concentration to low concentration (nanomolar range), achieving the same aggregation inhibition with reduced harmful effects and improved cost-effectiveness

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a highly efficient inhibitor molecule that provides prolonged activity at low doses, reducing the need for continuous high-dose administration and improving overall cost-effectiveness

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The low dose of compound (1) effectively inhibits amyloid beta toxicity, reducing the concentration at the site of action to less than 50 nM, thereby treating or preventing protein misfolding diseases with improved tolerability and cost-effectiveness.

Implementation Method 1

the stoichiometric ratio of 1:10 with amyloid beta molecules, to inhibit amyloid beta aggregation

Methodology Applied

Scientific EffectStoichiometric binding:

Data Source

PatentUS20250275944A1Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects

Publication Date: 2025.09.04 GALIMEDIX THERAPEUTICS INC

AI summary

Provided herein a method for treating or preventing a protein misfolding and deposition disease in a subject, by administering to the subject a low dose amount of compound (1). Provided herein is also a method for reversing or preventing the toxic effect of the misfolded and aggregated protein amyloid beta, by using compound (1) in a relative undersupply (reversed stoichiometric ratio) to achieve stronger detoxifying effects. Also provided dosages and administration thereof.